<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010581</url>
  </required_header>
  <id_info>
    <org_study_id>SC12267-5-2009</org_study_id>
    <nct_id>NCT01010581</nct_id>
  </id_info>
  <brief_title>SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>COMPONENT</acronym>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4SC AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4SC AG</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the efficacy, safety and pharmacokinetics of SC12267
      (4SC-101, 35 mg) in combination with methotrexate in comparison to methotrexate alone in the
      treatment of patients suffering from Rheumatoid Arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of SC12267 (4SC-101) in combination with methotrexate in patients with RA</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety of the combination of SC12267 (4SC-101) and methotrexate in patients with RA</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the plasma concentration (trough value) of SC12267 (4SC-101) after once daily application in combination with methotrexate after once weekly administration.</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SC12267 (4SC-101) + Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC12267 (4SC-101)</intervention_name>
    <description>oral administration</description>
    <arm_group_label>SC12267 (4SC-101) + Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>oral administration</description>
    <arm_group_label>SC12267 (4SC-101) + Methotrexate</arm_group_label>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>oral administration</description>
    <arm_group_label>SC12267 (4SC-101) + Methotrexate</arm_group_label>
    <arm_group_label>Placebo + Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Patients with active RA of functional classes I, II or III according to the criteria
             of American Rheumatism Association for RA

          -  DAS28(ESR) ≥ 4.5 (DAS28 formula with 4 variables using ESR)

          -  Patients who have received weekly doses of MTX (10-25 mg/week) for a minimum of 3
             months prior to Day 1 dosing, and who have received a stable MTX dose of 10-25 mg/week
             without any change in route or change in folic acid supplementation for at least 6
             weeks prior to Day 1 dosing

          -  Patients may receive up to 10 mg/day of oral prednisolone or steroid equivalent. Dose
             must have been stable for at least 30 days and must not be changed during the washout,
             screening and treatment periods, unless dictated by tolerability requirements

        Main Exclusion Criteria:

          -  Patients with RA of functional classes IV according to the criteria of American
             Rheumatism Association for RA

          -  Patients who have received any of the following treatments must abide by the indicated
             washout period:

               1. Leflunomide requires a 6 month washout period prior to Day 1 dosing

               2. Oral or injectable gold, azathioprine, penicillamine, anakinra require a 30 day
                  washout period prior to Day 1 dosing

               3. Cyclosporine, abatacept, etanercept, adalimumab, infliximab, and rituximab
                  require a 60 day washout period prior to Day 1 dosing

               4. Cyclophosphamide requires a 180 day washout period prior to Day 1 dosing

               5. Parenteral or intra-articular corticosteroids require a 30 day washout period
                  prior to Day 1 dosing

          -  Receipt of the following drugs within 4 weeks prior to dosing:

               1. Sulfasalazine

               2. Hydroxychloroquine

               3. Use of corticosteroids &gt; 10 mg/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanisław Sierakowski, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centrum Miriada, Prywatny Gabinet Specjalistyczny, Bialystok, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT &quot;Kaspela&quot; Department of Rheumatology</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consulting Centre &quot;Sv. Anna&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Multiprofile Transport Hospital &quot;Tsar Boris III&quot; Internal Clinic</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sveti Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Outpatient Clinic</name>
      <address>
        <city>Hlučín</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Center Mediscan</name>
      <address>
        <city>Praha 11</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Miriada, Prywatny Gabinet Specjalistyczny</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Centrum Badań Klinicznych s.c.</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Śląskie Centrum Osteoporozy</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Ośrodek ALL-MED</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Reumed</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr Hab. n. m. Leszek Szczepański</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poznański Ośrodek Medyczny NOVAMED</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Reumatologiczny</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ &quot;Nasz Lekarz&quot;</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Leczenia Chorób Cywilizacyjnych Sp. z o. o. S. K. A.</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Osteomed NZOZ Lecznica Specjalistów</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Materia Medica</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Hospital Sf. Maria</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Hospital &quot;Prof. Dr. Gerota&quot;</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Duomedical</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ianuli Med Consult</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital Cluj - Rheumatology clinic</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical County Hospital of Targoviste</name>
      <address>
        <city>Targoviste, Dambovita</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Prof. Dr. Mioara Banciu</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <last_update_submitted>February 29, 2012</last_update_submitted>
  <last_update_submitted_qc>February 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2012</last_update_posted>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>SC12267</keyword>
  <keyword>4SC-101</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

